Free Newsletter
Allergan stock soars on deal rumors
Wall Street is abuzz today with talk that Allergan may be on the block. Options traders have snapped up 13,000 April contracts--yep, that's 13,000, way beyond the normal volume. Apparently, they were set in motion by a web report that GlaxoSmithKline might be interested in the Botox-maker.
At press time, Allergan stock was up around 10 percent to over $47--after leaping by 13 percent earlier in the day, exceeding its 50-day moving average. Drug stocks in general were up, so some of Allergan's rise could be overall market pressure. And it's true that some analysts have tagged Allergan as a buy lately. And Fast Money yesterday recommended an Allergan buy for first thing today.
But professional traders are the options-buyers that swooped in for those thousands of contracts--and that's not a standard-issue up-market move. So what's going on? GSK won't comment, and Allergan won't either.
- see the story at Option Monster
- get more from The Street
- read the brief at MarketWatch
Related Articles:
Bristol, Allergan chiefs nab big raises
Anticipating sales declines, Allergan cuts 460
FDA approves Allergan's eyelash-growth drug
Cosmetic pharma remains steady in downturn
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: